Discovery and Structure−Activity Relationship of P1−P3 Ketoamide Derived Macrocyclic Inhibitors of Hepatitis C Virus NS3 Protease
Citations Over TimeTop 14% of 2008 papers
Abstract
Hepatitis C virus (HCV) infection is the major cause of chronic liver disease, leading to cirrhosis and hepatocellular carcinoma, and affects more than 200 million people worldwide. Although combination therapy of interferon-alpha and ribavirin is reasonably successful in treating majority of genotypes, its efficacy against the predominant genotype (genotype 1) is moderate at best, with only about 40% of the patients showing sustained virological response. Herein, the SAR leading to the discovery of a series of ketoamide derived P(1)-P(3) macrocyclic inhibitors that are more potent than the first generation clinical candidate, boceprevir (1, Sch 503034), is discussed. The optimization of these macrocyclic inhibitors identified a P(3) imide capped analogue 52 that was 20 times more potent than 1 and demonstrated good oral pharmacokinetics in rats. X-ray structure of 52 bound to NS3 protease and biological data are also discussed.
Related Papers
- → The Discovery and Development of Boceprevir: A Novel, First-generation Inhibitor of the Hepatitis C Virus NS3/4A Serine Protease(2013)41 cited
- → Ketoamide Resistance and Hepatitis C Virus Fitness in Val55 Variants of the NS3 Serine Protease(2012)33 cited
- → A new era in the treatment of chronic hepatitis C infection(2012)5 cited
- → Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: A meta-analysis on role of response predictors(2014)2 cited
- → PGI25 Cost Effectiveness of Boceprevir Plus Peginterferon Alpha and Ribavirin Versus Peginterferon Alfa Plus Ribavirin in the Treatment of Chronic Hepatitis C (CHC) in Previously Untreated Genotype I Patients(2012)